Breaking News Instant updates and real-time market news.

BPMC

Blueprint Medicines

$94.14 /

+0.25 (+0.27%)

18:09
04/11/21
04/11
18:09
04/11/21
18:09

Blueprint presents data from registrational PATHFINDER trial of AYVAKIT

Blueprint Medicines announced that multiple presentations across the company's leading systemic mastocytosis program were reported at the virtual American Association for Cancer Research Annual Meeting 2021. The presentations focused on registrational PATHFINDER trial data of AYVAKIT in advanced SM, PIONEER Part 1 data highlighting the impact of AYVAKIT on skin manifestations of SM, and Phase 1 trial data for BLU-263, a next-generation KIT D816V inhibitor. Blueprint Medicines is developing AYVAKIT for advanced and non-advanced SM, and BLU-263 to further address the range of patient needs in non-advanced SM and other mast cell disorders. In a pre-specified interim analysis from the PATHFINDER trial, 32 patients who primarily received a starting dose of 200 mg once daily were evaluable for response, as of a data cutoff date of June 23, 2020. Combined with Phase 1 EXPLORER trial results, these data support Blueprint Medicines' marketing applications in advanced SM under review in the U.S. and Europe. Overall, 75 percent of patients had a confirmed response, which was defined as complete remission with full or partial recovery of peripheral blood counts, partial remission or clinical improvement. The median time to response was two months, and all responses were ongoing at a median follow-up of 10.4 months. The CRh rate was 19 percent, with a median time to CRh of 5.6 months. These results show that responses deepened over time at a rate consistent with the EXPLORER trial. The company said that AYVAKIT led to robust and durable benefits across a number of additional clinical activity measures. In new patient-reported outcomes data, AYVAKIT showed a statistically significant reduction in total symptom score after 40 weeks, as measured by the Advanced Systemic Mastocytosis Symptom Assessment Form. Treatment with AYVAKIT resulted in robust improvements in patient-reported quality of life, based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Across multiple measures of mast cell burden, AYVAKIT showed profound reductions in serum tryptase, bone marrow mast cells, KIT D816V allele burden and spleen volume. Consistent with previously disclosed data, AYVAKIT was generally well-tolerated in 62 patients enrolled in the PATHFINDER trial, and most adverse events were reported as Grade 1 or 2. The most common AEs were peripheral edema, periorbital edema, thrombocytopenia, anemia, neutropenia, diarrhea, nausea, vomiting and fatigue. Three patients discontinued AYVAKIT due to treatment-related AEs, and most patients have remained on treatment as of the data cutoff date. In non-advanced SM, skin symptoms frequently persist and can severely impact quality of life. To assess the effects of AYVAKIT on mast cell burden in skin lesions, skin biopsies were obtained at baseline and week 12 in Part 1 of the PIONEER trial. Immunohistochemistry tests were performed to determine the proportion of aberrant mast cells in skin tissue, based on expression of CD25, CD30 and other transmembrane receptors observed in SM. Skin lesional tissue at baseline had more CD30-positive than CD25-positive mast cells. Following 12 weeks of treatment, AYVAKIT significantly reduced the proportion of aberrant CD30-positive mast cells in skin lesions compared to placebo, as of a data cutoff date of December 4, 2020. These data expand on previously reported results showing the impact of AYVAKIT on skin manifestations of SM, and suggest that CD30 may be an important biomarker of aberrant mast cells in SM-related skin lesions. A placebo-controlled, Phase 1 trial evaluated the safety, tolerability and pharmacokinetics of BLU-263 in healthy volunteers. This AACR presentation reported on single ascending dose cohorts and multiple ascending dose cohorts, as of a data cutoff date of November 9, 2020. BLU-263 was well-tolerated across all doses studied, and all AEs were reported as Grade 1. Pharmacokinetic data showed dose-dependent increases in systemic exposure of BLU-263, with the half-life of BLU-263 supporting once-daily dosing. Based on these results, the company plans to evaluate BLU-263 at doses ranging from 25 to 100 mg once daily in Part 1 of the Phase 2/3 HARBOR trial in patients with non-advanced SM, which the company plans to initiate in mid-2021.

  • 12

    Apr

  • 16

    Jun

BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays

TODAY'S FREE FLY STORIES

Hot Stocks
Amazon plans to build first robotics fulfillment center in Louisiana » 15:36
05/07/21
05/07
15:36
05/07/21
15:36
AMZN

Amazon.com

$3,304.00 /

-3 (-0.09%)

Amazon plans to open its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$3,304.00 /

-3 (-0.09%)

AMZN Amazon.com
$3,304.00 /

-3 (-0.09%)

05/04/21 R5 Capital
Amazon.com upgraded to Buy from Hold at R5 Capital
04/30/21 Evercore ISI
Amazon price target raised to $4,500 from $4,000 at Evercore ISI
04/30/21 MKM Partners
Amazon.com price target raised to $4,075 from $3,975 at MKM Partners
04/30/21 Raymond James
Amazon.com price target raised to $4,125 from $4,000 at Raymond James
AMZN Amazon.com
$3,304.00 /

-3 (-0.09%)

AMZN Amazon.com
$3,304.00 /

-3 (-0.09%)

AMZN Amazon.com
$3,304.00 /

-3 (-0.09%)

AMZN Amazon.com
$3,304.00 /

-3 (-0.09%)

Options
Univar options imply 8.3% move in share price post-earnings » 15:34
05/07/21
05/07
15:34
05/07/21
15:34
UNVR

Univar

$24.32 /

+0.05 (+0.21%)

Pre-earnings options…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UNVR Univar
$24.32 /

+0.05 (+0.21%)

UNVR Univar
$24.32 /

+0.05 (+0.21%)

03/08/21 BofA
Univar downgraded to Underperform from Buy at BofA
11/06/20 Goldman Sachs
Univar downgraded to Neutral from Buy at Goldman Sachs
UNVR Univar
$24.32 /

+0.05 (+0.21%)

UNVR Univar
$24.32 /

+0.05 (+0.21%)

Recommendations
Standex price target raised to $113 from $110 at Barrington » 15:32
05/07/21
05/07
15:32
05/07/21
15:32
SXI

Standex

$101.80 /

+3.445 (+3.50%)

Barrington analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SXI Standex
$101.80 /

+3.445 (+3.50%)

SXI Standex
$101.80 /

+3.445 (+3.50%)

03/01/21 Barrington
Standex price target raised to $110 from $101 at Barrington
02/05/21 Barrington
Standex price target raised to $101 from $97 at Barrington
01/28/21 Barrington
Standex price target raised to $97 from $94 at Barrington
01/06/21 Barrington
Imax and Sirius XM among Barrington's best ideas for 2021
SXI Standex
$101.80 /

+3.445 (+3.50%)

SXI Standex
$101.80 /

+3.445 (+3.50%)

Recommendations
Fidus Investment price target raised to $19 from $16 at Raymond James » 15:31
05/07/21
05/07
15:31
05/07/21
15:31
FDUS

Fidus Investment

$17.76 /

+0.36 (+2.07%)

Raymond James analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FDUS Fidus Investment
$17.76 /

+0.36 (+2.07%)

03/01/21 Keefe Bruyette
Fidus upgraded to Outperform after 'strong' 2020 at Keefe Bruyette
03/01/21 B. Riley Securities
Fidus Investment price target raised to $16.50 from $14.50 at B. Riley
03/01/21 Keefe Bruyette
Fidus Investment upgraded to Outperform from Market Perform at Keefe Bruyette
11/24/20 B. Riley Securities
Fidus Investment price target raised to $12 from $10 at B. Riley Securities
FDUS Fidus Investment
$17.76 /

+0.36 (+2.07%)

Recommendations
Peloton price target lowered to $135 from $180 at JMP Securities » 15:27
05/07/21
05/07
15:27
05/07/21
15:27
PTON

Peloton

$84.01 /

+0.21 (+0.25%)

JMP Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PTON Peloton
$84.01 /

+0.21 (+0.25%)

PTON Peloton
$84.01 /

+0.21 (+0.25%)

09:28 Today Truist
Peloton price target lowered to $125 from $160 at Truist
08:13 Today Stifel
Peloton price target lowered to $140 from $170 at Stifel
07:55 Today Canaccord
Peloton price target lowered to $150 from $180 at Canaccord
07:53 Today Wedbush
Peloton price target lowered to $114 from $120 at Wedbush
PTON Peloton
$84.01 /

+0.21 (+0.25%)

PTON Peloton
$84.01 /

+0.21 (+0.25%)

PTON Peloton
$84.01 /

+0.21 (+0.25%)

PTON Peloton
$84.01 /

+0.21 (+0.25%)

Conference/Events
VSE Corp. management to meet virtually with Benchmark » 15:26
05/07/21
05/07
15:26
05/07/21
15:26
VSEC

VSE Corp.

$43.72 /

+0.385 (+0.89%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VSEC VSE Corp.
$43.72 /

+0.385 (+0.89%)

VSEC VSE Corp.
$43.72 /

+0.385 (+0.89%)

05/05/21
Fly Intel: Top five analyst initiations
05/05/21 B. Riley
B. Riley starts VSE with Buy, says 'flying under the radar'
05/05/21 B. Riley
VSE Corp. initiated with a Buy at B. Riley
03/19/21 Canaccord
VSE Corp. price target raised to $52 from $48 at Canaccord
VSEC VSE Corp.
$43.72 /

+0.385 (+0.89%)

  • 29
    Jan
VSEC VSE Corp.
$43.72 /

+0.385 (+0.89%)

Conference/Events
Herman Miller participates in a conference call with Benchmark » 15:25
05/07/21
05/07
15:25
05/07/21
15:25
MLHR

Herman Miller

$43.82 /

+0.42 (+0.97%)

Conference call with CFO…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MLHR Herman Miller
$43.82 /

+0.42 (+0.97%)

MLHR Herman Miller
$43.82 /

+0.42 (+0.97%)

09/18/20 Benchmark
Herman Miller price target raised to $40 from $30 at Benchmark
09/17/20 Sidoti
Herman Miller price target raised to $50 from $33 at Sidoti
06/30/20 Sidoti
Herman Miller upgraded to Buy from Neutral at Sidoti
05/22/20 Benchmark
Herman Miller initiated with a Buy at Benchmark
MLHR Herman Miller
$43.82 /

+0.42 (+0.97%)

MLHR Herman Miller
$43.82 /

+0.42 (+0.97%)

MLHR Herman Miller
$43.82 /

+0.42 (+0.97%)

Recommendations
Immunic price target raised to $56 from $55 at JMP Securities » 15:25
05/07/21
05/07
15:25
05/07/21
15:25
IMUX

Immunic

$12.77 /

+0.9 (+7.58%)

JMP Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IMUX Immunic
$12.77 /

+0.9 (+7.58%)

IMUX Immunic
$12.77 /

+0.9 (+7.58%)

04/15/21 Piper Sandler
Piper Sandler 'very encouraged' by Immunic Phase 2 EMPhASIS cohort 2 data
04/15/21 Aegis
Immunic initiated with a Buy at Aegis
03/24/21
Fly Intel: Top five analyst initiations
03/24/21 JMP Securities
Immunic initiated with an Outperform at JMP Securities
  • 05
    Aug
  • 10
    Jun
IMUX Immunic
$12.77 /

+0.9 (+7.58%)

Recommendations
Granite Point Mortgage price target raised to $14 from $13 at JMP Securities » 15:23
05/07/21
05/07
15:23
05/07/21
15:23
GPMT

Granite Point Mortgage

$13.27 /

+0.22 (+1.69%)

JMP Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GPMT Granite Point Mortgage
$13.27 /

+0.22 (+1.69%)

GPMT Granite Point Mortgage
$13.27 /

+0.22 (+1.69%)

04/26/21 JPMorgan
Granite Point Mortgage price target raised to $12 from $10 at JPMorgan
Recommendations
Carvana price target raised to $326 from $290 at JMP Securities » 15:21
05/07/21
05/07
15:21
05/07/21
15:21
CVNA

Carvana

$250.50 /

-12.83 (-4.87%)

JMP Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CVNA Carvana
$250.50 /

-12.83 (-4.87%)

CVNA Carvana
$250.50 /

-12.83 (-4.87%)

05/03/21
Fly Intel: Top five analyst upgrades
05/03/21 BofA
Carvana upgraded to Buy at BofA amid tighter new auto supply
05/03/21 BofA
Carvana upgraded to Buy from Neutral at BofA
04/07/21 Raymond James
Carvana initiated with a Market Perform at Raymond James
CVNA Carvana
$250.50 /

-12.83 (-4.87%)

  • 02
    Dec
  • 19
    May
CVNA Carvana
$250.50 /

-12.83 (-4.87%)

CVNA Carvana
$250.50 /

-12.83 (-4.87%)

CVNA Carvana
$250.50 /

-12.83 (-4.87%)

Options
McEwen Mining options imply 14.9% move in share price post-earnings » 15:19
05/07/21
05/07
15:19
05/07/21
15:19
MUX

McEwen Mining

$1.30 /

+0.05 (+4.00%)

Pre-earnings options…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MUX McEwen Mining
$1.30 /

+0.05 (+4.00%)

MUX McEwen Mining
$1.30 /

+0.05 (+4.00%)

09/29/20 Alliance Global Partners
McEwen Mining transferred with a Buy at Alliance Global Partners
09/14/20 Roth Capital
McEwen Mining resumed with a Buy at Roth Capital
MUX McEwen Mining
$1.30 /

+0.05 (+4.00%)

MUX McEwen Mining
$1.30 /

+0.05 (+4.00%)

Technical Analysis
NASDAQ market internals summary » 15:17
05/07/21
05/07
15:17
05/07/21
15:17
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 15:16
05/07/21
05/07
15:16
05/07/21
15:16
$NYE

NYSE Market Internals

/

+

Volume is average for…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

General news
U.S. consumer credit rose $25.8 B in March » 15:15
05/07/21
05/07
15:15
05/07/21
15:15
$ECON

Economic Data

/

+

U.S. consumer credit rose…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
    Conference/Events
    Hubbell participates in a conference call with Stephens » 15:10
    05/07/21
    05/07
    15:10
    05/07/21
    15:10
    HUBB

    Hubbell

    $199.77 /

    -0.04 (-0.02%)

    Conference call with CEO…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    HUBB Hubbell
    $199.77 /

    -0.04 (-0.02%)

    HUBB Hubbell
    $199.77 /

    -0.04 (-0.02%)

    10/27/20 Stephens
    Hubbell price target raised to $180 from $175 at Stephens
    10/15/20 Stephens
    Hubbell resumed with an Overweight at Stephens
    09/15/20 UBS
    Hubbell initiated with a Neutral at UBS
    HUBB Hubbell
    $199.77 /

    -0.04 (-0.02%)

    Conference/Events
    Kirby management to meet virtually with Stephens » 15:09
    05/07/21
    05/07
    15:09
    05/07/21
    15:09
    KEX

    Kirby

    $67.67 /

    +0.67 (+1.00%)

    Virtual Meeting to be…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return in 9 minutes

    Get Free Trial

    ShowHide Related Items >><<
    KEX Kirby
    $67.67 /

    +0.67 (+1.00%)

    KEX Kirby
    $67.67 /

    +0.67 (+1.00%)

    09:30 Today Gabelli
    Kirby downgraded to Hold at Gabelli on decelerating earnings growth after 2023
    08:38 Today Gabelli
    Kirby downgraded to Hold from Buy at Gabelli
    11/18/20 BofA
    Kirby upgraded to Buy at BofA on refinery utilization increase potential
    11/18/20 BofA
    Kirby upgraded to Buy from Neutral at BofA
    KEX Kirby
    $67.67 /

    +0.67 (+1.00%)

    General news
    March consumer credit up $25.8B vs. last month, consensus $17.7B  15:08
    05/07/21
    05/07
    15:08
    05/07/21
    15:08
    $ECON

    Economic Data

    /

    +

     
    ShowHide Related Items >><<
      Options
      U S Global Investors options imply 10.6% move in share price post-earnings » 15:04
      05/07/21
      05/07
      15:04
      05/07/21
      15:04
      GROW

      U.S. Global Investors

      $7.38 /

      +0.165 (+2.29%)

      Pre-earnings options…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      ShowHide Related Items >><<
      GROW U.S. Global Investors
      $7.38 /

      +0.165 (+2.29%)

      On The Fly
      Short Interest Report: Bearish positioning on Washington Federal, iRobot jump » 14:59
      05/07/21
      05/07
      14:59
      05/07/21
      14:59
      WAFD

      Washington Federal

      $33.02 /

      -0.15 (-0.45%)

      , IRBT

      iRobot

      $96.56 /

      -1.86 (-1.89%)

      , MVIS

      MicroVision

      $14.14 /

      +0.14 (+1.00%)

      , M

      Macy's

      $17.61 /

      +0.285 (+1.65%)

      , DAC

      Danaos

      $64.70 /

      +1.43 (+2.26%)

      , PGEN

      Precigen

      $6.52 /

      -0.08 (-1.21%)

      , BRN

      Barnwell Industries

      $2.88 /

      -0.12 (-4.00%)

      , IWF

      iShares Russell 1000 Growth

      $256.38 /

      +1.39 (+0.55%)

      , IWD

      iShares Russell 1000 Value

      $161.70 /

      +1.19 (+0.74%)

      Welcome to this week’s…

      ShowHide Related Items >><<
      WAFD Washington Federal
      $33.02 /

      -0.15 (-0.45%)

      IRBT iRobot
      $96.56 /

      -1.86 (-1.89%)

      MVIS MicroVision
      $14.14 /

      +0.14 (+1.00%)

      M Macy's
      $17.61 /

      +0.285 (+1.65%)

      DAC Danaos
      $64.70 /

      +1.43 (+2.26%)

      PGEN Precigen
      $6.52 /

      -0.08 (-1.21%)

      BRN Barnwell Industries
      $2.88 /

      -0.12 (-4.00%)

      WAFD Washington Federal
      $33.02 /

      -0.15 (-0.45%)

      IRBT iRobot
      $96.56 /

      -1.86 (-1.89%)

      02/12/21 Northland
      iRobot price target raised to $140 from $120 at Northland
      02/12/21 Citi
      iRobot price target raised to $140 from $95 at Citi
      02/11/21 JPMorgan
      iRobot upgraded to Overweight from Neutral at JPMorgan
      02/11/21 JPMorgan
      iRobot upgraded to Overweight from Neutral at JPMorgan
      MVIS MicroVision
      $14.14 /

      +0.14 (+1.00%)

      M Macy's
      $17.61 /

      +0.285 (+1.65%)

      04/19/21 JPMorgan
      Macy's price target raised to $16 from $15 at JPMorgan
      03/12/21 Jefferies
      Jefferies picks Macy's, Kohl's and Nordstrom as department store 'survivors'
      02/24/21 Credit Suisse
      Macy's price target raised to $13 from $7 at Credit Suisse
      02/24/21 Deutsche Bank
      Macy's price target raised to $16 from $15 at Deutsche Bank
      DAC Danaos
      $64.70 /

      +1.43 (+2.26%)

      03/29/21 Fearnley
      Danaos initiated with a Buy at Fearnley
      12/09/20 Jefferies
      Danaos price target raised to $18 from $13 at Jefferies
      09/28/20 Citi
      Danaos price target raised to $6.25 from $4.75 at Citi
      PGEN Precigen
      $6.52 /

      -0.08 (-1.21%)

      03/02/21 B. Riley Securities
      Precigen price target raised to $14 from $10 at B. Riley Securities
      02/25/21 Stifel
      Precigen initiated with a Buy at Stifel
      02/22/21 Wells Fargo
      Precigen initiated with an Overweight at Wells Fargo
      02/18/21
      Fly Intel: Top five analyst initiations
      BRN Barnwell Industries
      $2.88 /

      -0.12 (-4.00%)

      IWF iShares Russell 1000 Growth
      $256.38 /

      +1.39 (+0.55%)

      IWD iShares Russell 1000 Value
      $161.70 /

      +1.19 (+0.74%)

      WAFD Washington Federal
      $33.02 /

      -0.15 (-0.45%)

      IRBT iRobot
      $96.56 /

      -1.86 (-1.89%)

      MVIS MicroVision
      $14.14 /

      +0.14 (+1.00%)

      M Macy's
      $17.61 /

      +0.285 (+1.65%)

      PGEN Precigen
      $6.52 /

      -0.08 (-1.21%)

      • 22
        Jan
      • 24
        Nov
      MVIS MicroVision
      $14.14 /

      +0.14 (+1.00%)

      M Macy's
      $17.61 /

      +0.285 (+1.65%)

      IRBT iRobot
      $96.56 /

      -1.86 (-1.89%)

      MVIS MicroVision
      $14.14 /

      +0.14 (+1.00%)

      M Macy's
      $17.61 /

      +0.285 (+1.65%)

      DAC Danaos
      $64.70 /

      +1.43 (+2.26%)

      PGEN Precigen
      $6.52 /

      -0.08 (-1.21%)

      BRN Barnwell Industries
      $2.88 /

      -0.12 (-4.00%)

      IWF iShares Russell 1000 Growth
      $256.38 /

      +1.39 (+0.55%)

      IWD iShares Russell 1000 Value
      $161.70 /

      +1.19 (+0.74%)

      WAFD Washington Federal
      $33.02 /

      -0.15 (-0.45%)

      IRBT iRobot
      $96.56 /

      -1.86 (-1.89%)

      MVIS MicroVision
      $14.14 /

      +0.14 (+1.00%)

      M Macy's
      $17.61 /

      +0.285 (+1.65%)

      DAC Danaos
      $64.70 /

      +1.43 (+2.26%)

      PGEN Precigen
      $6.52 /

      -0.08 (-1.21%)

      Recommendations
      Tabula Rasa price target raised to $45 from $41 at Piper Sandler » 14:49
      05/07/21
      05/07
      14:49
      05/07/21
      14:49
      TRHC

      Tabula Rasa HealthCare

      $47.06 /

      +4.89 (+11.60%)

      Piper Sandler analyst…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      ShowHide Related Items >><<
      TRHC Tabula Rasa HealthCare
      $47.06 /

      +4.89 (+11.60%)

      TRHC Tabula Rasa HealthCare
      $47.06 /

      +4.89 (+11.60%)

      03/01/21
      Fly Intel: Top five analyst downgrades
      03/01/21 Truist
      Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
      03/01/21 Truist
      Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
      02/24/21 Piper Sandler
      Tabula Rasa HealthCare downgraded to Neutral from Overweight at Piper Sandler
      TRHC Tabula Rasa HealthCare
      $47.06 /

      +4.89 (+11.60%)

      Options
      Denison Mines options imply 6.4% move in share price post-earnings » 14:49
      05/07/21
      05/07
      14:49
      05/07/21
      14:49
      DNN

      Denison Mines

      $1.17 /

      +0.005 (+0.43%)

      Pre-earnings options…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return tomorrow

      Get Free Trial

      ShowHide Related Items >><<
      DNN Denison Mines
      $1.17 /

      +0.005 (+0.43%)

      DNN Denison Mines
      $1.17 /

      +0.005 (+0.43%)

      03/24/21 Raymond James
      Denison Mines price target raised to C$1.70 from C$1.20 at Raymond James
      02/25/21 TD Securities
      Denison Mines price target raised to C$1.55 from C$1 at TD Securities
      02/10/21 Raymond James
      Denison Mines price target raised to C$1.20 from C$1.15 at Raymond James
      01/21/21 Canaccord
      Denison Mines price target raised to C$1.10 from C$0.90 at Canaccord
      DNN Denison Mines
      $1.17 /

      +0.005 (+0.43%)

      Recommendations
      Intel should regain industry leadership via investments, says Tigress Financial » 14:48
      05/07/21
      05/07
      14:48
      05/07/21
      14:48
      INTC

      Intel

      $57.54 /

      +0.36 (+0.63%)

      Tigress Financial analyst…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      ShowHide Related Items >><<
      INTC Intel
      $57.54 /

      +0.36 (+0.63%)

      INTC Intel
      $57.54 /

      +0.36 (+0.63%)

      05/04/21 Stifel
      Intel spending plans show new CEO 'gets it,' says Stifel
      04/29/21 Needham
      MaxLinear price target raised to $50 from $45 at Needham
      04/23/21 Needham
      Intel price target lowered to $70 from $74 at Needham
      04/23/21 Morgan Stanley
      Intel report offered 'no big surprises,' says Morgan Stanley
      INTC Intel
      $57.54 /

      +0.36 (+0.63%)

      INTC Intel
      $57.54 /

      +0.36 (+0.63%)

      INTC Intel
      $57.54 /

      +0.36 (+0.63%)

      INTC Intel
      $57.54 /

      +0.36 (+0.63%)

      Options
      Bridgetown Holdings call volume above normal and directionally bullish » 14:45
      05/07/21
      05/07
      14:45
      05/07/21
      14:45
      BTWN

      Bridgetown Holdings

      $10.15 /

      -0.04 (-0.39%)

      Bullish option flow…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return tomorrow

      Get Free Trial

      ShowHide Related Items >><<
      BTWN Bridgetown Holdings
      $10.15 /

      -0.04 (-0.39%)

      BTWN Bridgetown Holdings
      $10.15 /

      -0.04 (-0.39%)

      Recommendations
      Ruth's Hospitality price target raised to $33 from $30 at Stephens » 14:39
      05/07/21
      05/07
      14:39
      05/07/21
      14:39
      RUTH

      Ruth's Hospitality

      $27.31 /

      +0.62 (+2.32%)

      Stephens analyst James…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      ShowHide Related Items >><<
      RUTH Ruth's Hospitality
      $27.31 /

      +0.62 (+2.32%)

      RUTH Ruth's Hospitality
      $27.31 /

      +0.62 (+2.32%)

      03/05/21 Stephens
      Ruth's Hospitality price target raised to $25 from $19 at Stephens
      11/02/20 Raymond James
      Ruth's Hospitality upgraded to Strong Buy from Outperform at Raymond James
      11/02/20 Raymond James
      Ruth's Hospitality upgraded to Strong Buy from Outperform at Raymond James
      10/12/20
      Fly Intel: Top five analyst upgrades
      RUTH Ruth's Hospitality
      $27.31 /

      +0.62 (+2.32%)

      • 21
        May
      Recommendations
      ACM Research price target lowered to $110 from $130 at Roth Capital » 14:37
      05/07/21
      05/07
      14:37
      05/07/21
      14:37
      ACMR

      ACM Research

      $75.73 /

      +0.05 (+0.07%)

      Roth Capital analyst Suji…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return tomorrow

      Get Free Trial

      ShowHide Related Items >><<
      ACMR ACM Research
      $75.73 /

      +0.05 (+0.07%)

      ACMR ACM Research
      $75.73 /

      +0.05 (+0.07%)

      12/16/20 Roth Capital
      ACM listing in China set for Q1 with Verification Report, says Roth Capital
      10/27/20 Jefferies
      ACM Research initiated with a Buy at Jefferies
      10/09/20 Stifel
      Short report on ACM Research 'misleading' and 'erroneous,' says Stifel
      10/01/20 Roth Capital
      Roth Capital encouraged by milestone in ACM Research's STAR Market IPO plan
      ACMR ACM Research
      $75.73 /

      +0.05 (+0.07%)

      ACMR ACM Research
      $75.73 /

      +0.05 (+0.07%)

      Get Full Fly Access

      Breaking market intelligence sent straight to you
      Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
      Up-to-date information on important industry events
      Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
      News focused on the companies in your portfolio
      Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.